OTDOncology Treatment Discovery3083-49962981-8079Bio-Byword Scientific Publishing Pty. Ltd.10.26689/otd.v2i1.6374ArticleAnalysis of the Treatment for Advanced Microsatellite Stable Colorectal Cancer in Middle-Aged and Elderly Peoplehttps://artdesignp.com/journal/OTD/2/1/10.26689/otd.v2i1.6374ZhouZhi,WangYanchun2024212024-03-29Microsatellite stabilized (MSS) rectal cancer is a highly prevalent cancer in the middle-aged and elderly population. There exists some expertise in detecting and evaluating the chemotherapy effect in advanced colorectal cancer patients. Multiple studies have combined targeted therapy, chemotherapy, and immunotherapy as a breakthrough. Programmed cell death protein 1 (PD-1) inhibitors have certain therapeutic effects in the treatment of MSS rectal cancer patients. The combination of PD-1 inhibitors and furoquinib can improve the disease control rate (DCR) and progression- free survival (PFS) in colorectal cancer (CRC) patients with advanced MSS, and the adverse reactions are controllable. The combination of erlotinib hydrochloride and Xindilizumab was more effective in treating MSS-type colorectal cancer patients than clinical standard treatment. This study analyzes the various treatment methods for MSS-type CRC in middle- aged and elderly people to provide a reference basis in clinical practice.

Led T, Uram JN, Wang H, et al., 2015, PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med, 372(26): 2509–2520.

Dudley JC, Lin MT, Le DT, et al., 2016, Microsatellite Instability as A Biomarker for PD-1 Blockade. Clin Cancer Res, 22(4): 813–820.

Gou H, Fang L, Zhong X, 2023, The Relationship Between KRAS, NRAS, and BRAF Gene Mutations and Liver Metastasis in Colorectal Cancer. Journal of Kunming Medical University, 44(1): 19–24.

Sung H, Ferlay J, Siegel RL, et al., 2021, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 71(3): 209–249.

Xia C, Dong X, Li H, et al., 2022, Cancer Statistics in China and the United States, 2022: Profiles, Trends, and Determinants. Chin Med J (Engl), 135(5): 584–590.

Hu W, Ying X, Wang J, 2020, The Significance Analysis of MSI in Evaluating The Chemotherapy Efficacy of Advanced Colorectal Cancer. Jiangxi Pharmaceutical, 55(5): 539–541.

Wang L, Mao H, Tong J, et al., 2019, The Impact of Mismatch Repair/Microsatellite Instability on Chemotherapy Sensitivity and Prognosis of Advanced Colorectal Cancer. Chinese Medical Journal, 16(8): 108–111.

Wu Y, Bai X, Wang Z, 2019, Analysis and Study of Tumor-Associated Macrophages and Gene Phenotypes in Colorectal Cancer. Modern Chinese Medicine, 57(17): 36–40.

Cheng C, Jie Z, Wang J, et al., 2021, The Correlation Between Microsatellite Instability and The Efficacy and Prognosis of Palliative Chemotherapy in Patients with Advanced Colorectal Cancer. Journal of Henan University (Medical Edition), 40(4): 269–272.

Wu Y, Zhang C, Liang F, et al., 2015, The Impact of Microsatellite Instability on Chemotherapy Response and Prognosis in Patients with Stage IV Colorectal Cancer. Chinese Journal of Cancer, 25(7): 522–527.

Zhu Z, Ji F, 2023, Treatment of Late-Stage Colorectal Cancer with KRAS Mutant Microsatellite Stable Type. Clinical Medical Progress, 13(5): 8128–8134.

Zhou L, Ge X, Xu R, et al., 2022, Analysis of Therapeutic Effects of PD-1 Inhibitors on Microsatellite Stable Colorectal Cancer Patients. Journal of Digestive Oncology (Electronic Edition), 14(2): 153–157.

Luo X, Chen J, Shi W, et al., 2022, The Efficacy and Safety of Regorafenib Combined With PD-1 Inhibitors in Advanced Microsatellite Stable Colorectal Cancer. Chinese Journal of Cancer Prevention and Treatment, 14(5): 521– 527.

Li R, Xing X, Liu Y, et al., 2023, Clinical Efficacy Observation of Programmed Cell Death Protein-1 Inhibitor Combined with Furquinib in The Treatment of Advanced Colorectal Cancer. Journal of Digestive Oncology (Electronic Edition), 15(2): 126–131.

Jia Z, Xu J, Da J, et al., 2023, Clinical Efficacy and Safety Observation of The Combination of Furoquinib and Programmed Death Receptor-1 Inhibitors in The Treatment of Microsatellite Stable or Mismatched Repair Normal Metastatic Colorectal Cancer. Journal of Clinical Military Medicine, 51(9): 945–948.

Yu W, Wang X, Zhao L, et al., 2023, Clinical Observation of Chemotherapy Combined with Karelizumab for Unsurgical Microsatellite Stable Colorectal Cancer. China Pharmacy, 34(10): 1242–1246.

Sun L, Yan Y, Xu Y, et al., 2022, Current Status and Efficacy Analysis of Combined Traditional Chinese and Western Medicine Treatment for Advanced Colorectal Cancer Based on A Single Center Retrospective Real-World Study. Journal of Traditional Chinese Oncology, 4(1): 1–23.

Ma Q, Yang Y, Li X, et al., 2022, The Therapeutic Effect of Combination Therapy with Carolizumab and Apatinib on Advanced Colorectal Cancer with Different Microsatellite Status. Henan Medical Research, 31(7): 1194–1198.

Gi L, Yang W, 2022, One Case of Advanced Rectal Cancer Treated with Regorafenib. Electronic Journal of Liver Cancer, 9(2): 49–52.

Zhu L, Liu Q, Xiao M, et al., 2023, Clinical Efficacy and Impact on Immune Function of Patients with Microsatellite Stable Advanced Colon Cancer Treated with Xindilimab Combined with Furoquantinib. Chinese Journal of Immunology, 39(9): 1922–1927.

Ji Y, Yang X, Meng X, et al., 2021, Observation of The Therapeutic Effect of Combination Therapy of Amlotinib Hydrochloride and Xindilimab on Microsatellite Stable Colorectal Cancer after Standard Treatment Failure. Journal of Xinxiang Medical College, 38(8): 719–724.